WO2004097009A3 - Procédé d'identification d'agents d'activation ou d'inhibition de ikki - Google Patents

Procédé d'identification d'agents d'activation ou d'inhibition de ikki Download PDF

Info

Publication number
WO2004097009A3
WO2004097009A3 PCT/EP2004/004604 EP2004004604W WO2004097009A3 WO 2004097009 A3 WO2004097009 A3 WO 2004097009A3 EP 2004004604 W EP2004004604 W EP 2004004604W WO 2004097009 A3 WO2004097009 A3 WO 2004097009A3
Authority
WO
WIPO (PCT)
Prior art keywords
ikki
inhibit
activate
identify agents
agents
Prior art date
Application number
PCT/EP2004/004604
Other languages
English (en)
Other versions
WO2004097009A2 (fr
Inventor
Vladimir Kravchenko
Frank Mercurio
Richard J Ulevitch
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Scripps Research Inst
Vladimir Kravchenko
Frank Mercurio
Richard J Ulevitch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Scripps Research Inst, Vladimir Kravchenko, Frank Mercurio, Richard J Ulevitch filed Critical Novartis Ag
Publication of WO2004097009A2 publication Critical patent/WO2004097009A2/fr
Publication of WO2004097009A3 publication Critical patent/WO2004097009A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à des procédés pour l'utilisation d'agents qui accroissent ou diminuent l'expression ou l'activité de IKKi pour la régulation de processus cellulaires, tels que l'inflammation, la différenciation cellulaire, la prolifération cellulaire, la régénération tissulaire, la neurodégénérescence et l'activation du complément. L'invention a également trait à un procédé d'identification d'agents qui accroissent ou diminuent l'expression ou l'activité de IKKi.
PCT/EP2004/004604 2003-05-01 2004-04-30 Procédé d'identification d'agents d'activation ou d'inhibition de ikki WO2004097009A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46766503P 2003-05-01 2003-05-01
US60/467,665 2003-05-01

Publications (2)

Publication Number Publication Date
WO2004097009A2 WO2004097009A2 (fr) 2004-11-11
WO2004097009A3 true WO2004097009A3 (fr) 2005-02-17

Family

ID=33418453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004604 WO2004097009A2 (fr) 2003-05-01 2004-04-30 Procédé d'identification d'agents d'activation ou d'inhibition de ikki

Country Status (1)

Country Link
WO (1) WO2004097009A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540775A1 (fr) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag Usage medical de tbk-1 ou d'inhibiteurs de celui-ci
JP2011518126A (ja) * 2008-03-25 2011-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ＩＫＫｉ阻害剤の処置方法およびスクリーニング方法、ならびに関連するＩＫＫｉ診断方法
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
EP2991647B1 (fr) 2013-05-02 2019-04-24 The Regents Of The University Of Michigan Amléxanox deutéré avec une stabilité métabolique améliorée
US10370664B2 (en) 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
WO2016179351A1 (fr) 2015-05-05 2016-11-10 Northwestern University Traitement de de dyskinésies induites par la lévodopa
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
US11554103B2 (en) 2016-11-10 2023-01-17 Northwestern University Compositions and methods to reduce pharmaceutical-induced toxicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039308A1 (fr) * 1998-12-24 2000-07-06 Glaxo Wellcome Kabushiki Kaisha Kinase ikk3
EP1043397A1 (fr) * 1998-10-26 2000-10-11 Japan Science and Technology Corporation IDENTIFICATION D'UN NOUVEAU SUBSTRAT I-TRAF DE LA KINASE IKK-i

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043397A1 (fr) * 1998-10-26 2000-10-11 Japan Science and Technology Corporation IDENTIFICATION D'UN NOUVEAU SUBSTRAT I-TRAF DE LA KINASE IKK-i
WO2000039308A1 (fr) * 1998-12-24 2000-07-06 Glaxo Wellcome Kabushiki Kaisha Kinase ikk3

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FITZGERALD KATHERINE A ET AL: "IKKepsilon and TBKI are essential components of the IRF3 signaling pathway.", NATURE IMMUNOLOGY, vol. 4, no. 5, May 2003 (2003-05-01), pages 491 - 496, XP002297126, ISSN: 1529-2908 *
KRAVCHENKO VLADIMIR V ET AL: "IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 29, 18 July 2003 (2003-07-18), pages 26612 - 26619, XP002297127, ISSN: 0021-9258 *
PETERS^1 R T ET AL: "A new family of IKK-related kinases may function as IkappaB kinase kinases", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1471, no. 2, 26 January 2001 (2001-01-26), pages M57 - M62, XP004248862, ISSN: 0304-419X *

Also Published As

Publication number Publication date
WO2004097009A2 (fr) 2004-11-11

Similar Documents

Publication Publication Date Title
WO2006023649A3 (fr) Traitement de la sclerose en plaques grave
WO2004018058A3 (fr) Composes, compositions et methodes
WO2006113432A3 (fr) Composes, compositions et procedes
WO2006138418A3 (fr) Amelioration de la performance cognitive avec des activateurs de sirtuine
AU2005302085A1 (en) Copper containing materials for treating wounds, burns and other skin conditions
WO2003094839A8 (fr) Composes, compositions et procedes
WO2007140002A3 (fr) Méthode pour traiter un lymphome non hodgkinien
WO2007014278A3 (fr) Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
WO2005113590A3 (fr) Propeptides de bmp10 et procédés correspondants
WO2004080430A3 (fr) Procedes pour ameliorer la qualite de la peau
WO2003088903A3 (fr) Composés, compositions, et procédés
WO2006055871A3 (fr) Traitement de la sclerose en plaques
WO2004058148A3 (fr) Inhibiteurs de la kinesine mitotique
WO2005065269A3 (fr) Compositions et methodes permettant de ralentir l'apparition des rides cutanees
WO2005007141A3 (fr) Inhibiteurs de l'ubiquitine ligase et methodes associees
WO2004006853A3 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
WO2004058700A3 (fr) Inhibiteurs de kinesine mitotique
WO2004009036A3 (fr) Composes, compositions et procedes
WO2006039691A3 (fr) Morphine et precurseurs de morphine
WO2006069253A3 (fr) Peptides en trefles et methodes de traitement des troubles proliferatifs au moyen desdits peptides
WO2006013261A3 (fr) Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire.
WO2004097009A3 (fr) Procédé d'identification d'agents d'activation ou d'inhibition de ikki
WO2004006865A3 (fr) Composes, compositions et methodes
WO2006044155A3 (fr) Compositions ophtalmiques comprenant un lubrifiant, un agent deturgescent, ainsi qu'un glycosaminoglycane et methodes d'utilisation de ces dernieres
WO2004026226A3 (fr) Composes, compositions et procedes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase